Peritoneal Effluent MMP-2 and PAI-1 in Encapsulating Peritoneal Sclerosis

American Journal of Kidney Diseases

Volumn 65, Issue 5, 2015, Pages 748-753

  Lopes Barreto, Deirisa ^a   Struijk, Dirk G ^a,b   Krediet, Raymond T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dianet Foundation   (Netherlands)

Author keywords

Biomarkers; diagnostic accuracy; early detection; encapsulating peritoneal sclerosis (EPS); end stage renal disease (ESRD); matrix metalloproteinase 2 (MMP 2); peritoneal dialysis (PD); peritoneal effluent; plasminogen activator inhibitor 1 (PAI 1)

Indexed keywords

GELATINASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; BIOLOGICAL MARKER; DIALYSIS FLUID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIALYSATE; DISEASE COURSE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; LIMIT OF DETECTION; MALE; NEPHROLOGIST; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RADIOLOGIST; TREATMENT DURATION; WATER TRANSPORT; ADVERSE EFFECTS; CHEMISTRY; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; DIALYSIS SOLUTIONS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; YOUNG ADULT;

EID: 84929028485     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.10.022     Document Type: Article

References (26)

1. R.J. Rigby, and C.M. Hawley Sclerosing peritonitis: the experience in Australia Nephrol Dial Transplant 13 1 1998 154 159
2. G. Balasubramaniam, E.A. Brown, A. Davenport, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis Nephrol Dial Transplant 24 10 2009 3209 3215
3. D.W. Johnson, Y. Cho, B.E. Livingston, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes Kidney Int 77 10 2010 904 912
4. J.W. Dobbie, K.W. Lloyd, and C.A. Gall Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients Adv Perit Dial 6 1990 3 12
5. M. Yanez-Mo, E. Lara-Pezzi, R. Selgas, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells N Engl J Med 348 5 2003 403 413
6. M.A. Mateijsen, A.C. van der Wal, P.M. Hendriks, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis Perit Dial Int 19 6 1999 517 525
7. J.D. Williams, K.J. Craig, N. Topley, et al. Morphologic changes in the peritoneal membrane of patients with renal disease J Am Soc Nephrol 13 2 2002 470 479
8. G. Garosi, N. Di Paolo, G. Sacchi, and E. Gaggiotti Sclerosing peritonitis: a nosological entity Perit Dial Int 25 suppl 3 2005 S110 S112
9. N. Braun, D.M. Alscher, P. Fritz, et al. Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis Nephrol Dial Transplant 26 3 2011 1033 1041
10. D.E. Sampimon, Coester, D.G. Struijk, and R.T. Krediet The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis Nephrol Dial Transplant 26 1 2011 291 298
11. D. Lopes Barreto, and R.T. Krediet Current status and practical use of effluent biomarkers in peritoneal dialysis Am J Kidney Dis 62 4 2013 823 833
12. D. Lopes Barreto, A.M. Coester, D.G. Struijk, and R.T. Krediet Can effluent matrix metalloproteinase and plasminogen activator inhibitor-1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis? Perit Dial Int 33 5 2013 529 537
13. T. Klein, and R. Bischoff Physiology and pathophysiology of matrix metalloproteases Amino Acids 41 2 2011 271 290
14. J. Schneiderman, and D.J. Loskutoff Plasminogen activator inhibitors Trends Cardiovasc Med 1 3 1991 99 102
15. C. Della, and D.J. Loskutoff Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease Thromb Haemost 93 4 2005 631 640
16. J.P. Rougier, S. Guia, J. Hagege, G. Nguyen, and P.M. Ronco PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1 Kidney Int 54 1 1998 87 98
17. I. Hirahara, M. Inoue, T. Umino, O. Saito, S. Muto, and E. Kusano Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan Nephrol Dial Transplant 26 5 2011 1695 1701
18. A.W. De Boer, M. Levi, and R.E. Reddingins Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis Paediatr Nephrol 13 4 1999 284 287
19. R. Selgas, M.V. Cuesta, C. Rinon, et al. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-1) levels in plasma and peritoneal effluent in patients on CAPD Adv Perit Dial 8 1992 160 165
20. P.M. Hendriks, M.M. Ho-dac-Pannekeet, and T.M. van Gulik et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics Perit Dial Int 17 2 1997 136 143
21. M.M. Pannekeet, A.L. Imholz, D.G. Struijk, et al. The standard permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients Kidney Int 48 3 1995 866 875
22. D.E. Sampimon, M.R. Korte, D. Lopes Barreto, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study Perit Dial Int 30 2 2010 163 169
23. I. Hirahara, M. Inoue, K. Okuda, Y. Ando, S. Muto, and E. Kusano The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulation peritoneal sclerosis during peritoneal dialysis: a multicentre study in Japan Nephrol Dial Transplant 22 2 2007 560 567
24. P.J. Margetts, P. Bonniaud, L. Liu, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum J Am Soc Nephrol 16 2 2005 425 436
25. A.A. Eddy, and A.B. Fogo Plasminogen activatior inhibitor-1 in chronic kidney disease: evidence and mechanisms of action J Am Soc Nephrol 17 11 2006 2999 3012
26. K. Opatrny, S. Opatrna, L. Vit, and K. Opatrny Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis Am J Nephrol 18 3 1998 186 192